NICE issues Remicade guidance for UC

The U.K.'s NICE issued a preliminary appraisal recommending use of Remicade infliximab from Johnson & Johnson (NYSE:JNJ) and Schering-Plough (NYSE:SGP) to treat acute exacerbations of severely active ulcerative colitis (UC) only in patients in whom cyclosporin is contraindicated. The closing date for comments is Sept. 3, with a second appraisal committee meeting scheduled for Sept. 18. The appraisal can be found at http://www.nice.org.uk/guidance/index.jsp?action=article&o=41570 ...